Market Closed - Nasdaq Copenhagen 10:46:23 2024-04-18 am EDT 5-day change 1st Jan Change
1.254 DKK -1.57% Intraday chart for BioPorto A/S -3.83% -40.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BioPorto Names New Chief Legal Officer MT
Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024 CI
Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election CI
BioPorto A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioPorto Makes Interim CEO Permanent MT
BioPorto A/S Appoints Peter Mørch Eriksen as Permanent Group CEO CI
Bioporto A/S Announces Peter Mørch Eriksen Will Not Stand for Re-Election to the Board of Directors CI
Transcript : BioPorto A/S - Special Call
BioPorto A/S Provides Revenue Guidance for the Full Year 2024 CI
Roche: extended collaboration with Denmark's BioPorto CF
BioPorto Expands Global Distribution Partnership with Roche Diagnostics MT
Roche Diagnostics and BioPorto A/S Expand Collaboration CI
BioPorto CEO Steps Down; Interim Successor Appointed MT
BioPorto A/S Announces CEO Changes CI
Transcript : BioPorto A/S - Special Call
BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States CI
BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member CI
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023
Transcript : BioPorto A/S, Q3 2023 Earnings Call, Nov 01, 2023
BioPorto A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023 CI
BioPorto CFO Steps Down; Search for Successor Underway MT
Bioporto A/S Announces Resignation of Neil Goldman as CFO CI
Transcript : BioPorto A/S, Q2 2023 Earnings Call, Aug 01, 2023
BioPorto A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart BioPorto A/S
More charts
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.254 DKK
Average target price
5 DKK
Spread / Average Target
+298.72%
Consensus
  1. Stock Market
  2. Equities
  3. BIOPOR Stock
  4. News BioPorto A/S
  5. BioPorto Expands Global Distribution Partnership with Roche Diagnostics